Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

In the late 1960s Miles Vaughan Williams, a member of the staff in the Oxford Department of Pharmacology and Fellow of Hertford College (1955-85), introduced a novel classification of drugs used to treat cardiac arrhythmias. This scheme has been very widely used around the world and has led to the development of new drugs that have saved countless lives. Our understanding of the control of cardiac rhythm has developed in that time and a group of cardiovascular scientists from Oxford, Cambridge and Beijing led by Associate Professor Ming Lei decided that the time was ripe to modernise the classification and to celebrate the centenary of the birth of Vaughan Williams.

Together they have now published a comprehensive modern classification, based upon the original version, in the leading journal ‘Circulation’.

Findings over the past 5 decades from studies of different molecular drug targets, their mechanisms of action, and consequent clinical effects have led to the need to revise the classification. The modernised Oxford classification augments Vaughan Williams’s original framework covering the actions of sodium, potassium and calcium ions and the effects on these of the nervous system (Class I-IV). Novel categories now relate to altered heart rates (Class 0), mechanical stretch (Class V); intercellular electrical communication (Class IV) and longer term structural change (Class VII). The scheme then draws attention to multiple drug targets and actions and possible adverse, even pro-arrhythmic, effects.

This clarified classification of both the actions and therapeutic applications of both established drugs and novel drugs under investigation will improve current and future treatment of cardiac arrhythmias. It will encourage a rational clinical use of existing available anti-arrhythmic drugs in relationship to their particular mechanisms of action. It will aid identification and development of novel drugs relating their future clinical applications to their molecular mechanisms of action.  

The classification commemorates and advances the landmark contributions of Miles Vaughan Williams (https://en.wikipedia.org/wiki/Miles_Vaughan_Williams) to the physiology of the heart that began this quest nearly half a century ago on this centenary of his birth. It is likely that the new classification will have an enduring impact on cardiological medicine.

See the text of the paper here:

https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.118.035455

https://www.ahajournals.org/doi/suppl/10.1161/circulationaha.118.035455.

Similar stories

Travels with Vignesh

CRM General

Vignesh Murugesan, a Postdoctoral Researcher in Department of Physiology, Anatomy & Genetics (DPAG), describes how he found his way from the large metropolitan town of Chennai in India to studying regenerative medicine here in Oxford, via an 8 year stint in Sweden.

Genetic breakthrough to target care for deadly heart condition

CRE Research

Professor Watkins and his team have found a new type of genetic change in the DNA of people with hypertrophic cardiomyopathy (HCM) - a silent killer amongst families that can cause sudden death in young people due to the thickening of the heart muscle.

Earliest origins of the forming heart identified

CRE Research

The earliest known progenitor of the outermost layer of the heart has been characterised for the first time and linked to the development of other critical cell types in the developing heart in a new paper from the Srinivas group led by BHF Immediate Fellow Dr Richard Tyser.

Professor Sir Rory Collins awarded the MRC Millennium Medal 2020

CRE Research

Professor Sir Rory Collins, Head of the Nuffield Department of Population Health, and Principal Investigator and Chief Executive of UK Biobank, has been awarded the Medical Research Council (MRC) Millennium Medal 2020, the MRC’s most prestigious personal award.

New MRI technique could detect early signs of heart failure in cancer patients following chemotherapy

CRE Publication Research

New research led by Oxford BHF CRE Intermediate Transition Fellow Dr Kerstin Timm shows that a recently developed imaging technique pioneered by the Tyler Group can detect early metabolic changes in the heart caused by a commonly used chemotherapy drug, which is known to increase risk of heart failure in cancer survivors.